

# CITATION REPORT

List of articles citing

Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications

DOI: 10.1056/nejm199605163342002

New England Journal of Medicine, 1996, 334, 1287-91.

**Source:** <https://exaly.com/paper-pdf/26754840/citation-report.pdf>

**Version:** 2024-04-19

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
534	Differential effect of cimetidine on serum concentrations of carbamazepine and phenytoin. <b>1985</b> , 35, 562-5		24
533	Rheumatology. Inflammation and HIV infection: a friendly connection. <b>1996</b> , 348 Suppl 2, sII24		0
532	Rheumatoid arthritis. <b>1996</b> , 10, 49-56		
531	Combination DMARD therapy for rheumatoid arthritis: a step closer to the goal. <b>1996</b> , 55, 781-3		15
530	Treatment of Rheumatoid Arthritis. <i>New England Journal of Medicine</i> , <b>1996</b> , 335, 821-823	59.2	
529	Methotrexate update. <b>1996</b> , 25, 341-4		32
528	The rational use of methotrexate in rheumatoid arthritis and other rheumatic diseases. <b>1997</b> , 36, 1196-204		68
527	Recombinant human tumor necrosis factor receptor (p75) Fc fusion protein (TNFR:Fc) in rheumatoid arthritis. <b>1997</b> , 31, 1335-8		78
526	Dilemmas of low dosage glucocorticoid treatment in rheumatoid arthritis: considerations of timing. <b>1997</b> , 56, 1-4		11
525	Combination of sulphasalazine and methotrexate versus the single components in early rheumatoid arthritis: a randomized, controlled, double-blind, 52 week clinical trial. <b>1997</b> , 36, 1082-8		154
524	Sulphasalazine in the treatment of rheumatoid arthritis. <b>1997</b> , 36, 382-6		48
523	A retrospective study of treating RA patients with various combinations of slow-acting antirheumatic drugs in a county hospital. <b>1997</b> , 26, 440-3		10
522	Immunosuppressive and cytotoxic pharmacotherapy for pulmonary disorders. <b>1997</b> , 155, 395-420		135
521	Education, self-care, and outcomes of rheumatic diseases: further challenges to the "biomedical model" paradigm. <b>1997</b> , 10, 283-8		31
520	Combination of second-line antirheumatic drugs. <b>1997</b> , 29, 169-73		7
519	Methotrexate in rheumatoid arthritis: folate supplementation should always be given. <b>1997</b> , 8, 164-75		9
518	Rheumatoid arthritis: current clinical and research directions. <b>1997</b> , 6, 627-38		30

517	Treatment of rheumatoid arthritis. <b>1997</b> , 81, 57-84	9
516	Methotrexate use in rheumatoid arthritis. <b>1997</b> , 23, 779-96	53
515	Rheumatoid Arthritis. <b>1997</b> , 1, 141-153	5
514	Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. <b>1997</b> , 350, 309-18	801
513	Rheumatoid arthritis: not yet curable with early intensive therapy. <b>1997</b> , 350, 304-5	14
512	Arthritis and the community. <b>1997</b> , 166, 344-5	1
511	12. Toxicity of antirheumatic drugs. <b>1997</b> , 166, 378-383	8
510	The pathophysiology and treatment of rheumatoid arthritis. <b>1997</b> , 40, 595-7	61
509	Nonsteroidal antiinflammatory drugs in rheumatoid arthritis and osteoarthritis: support for the concept of "responders" and "nonresponders". <b>1997</b> , 40, 1944-54	53
508	Treatment of refractory rheumatoid arthritis with low-dose cyclophosphamide. Long-term follow-up of 108 patients. <b>1998</b> , 57, 101-7	6
507	Combination therapy with biologic agents in rheumatoid arthritis: perils and promise. <b>1998</b> , 41, 1548-51	26
506	Methotrexate and emerging therapies. <b>1998</b> , 24, 651-8	17
505	Early, aggressive therapy for rheumatoid arthritis?. <b>1998</b> , 11, 5-8	
504	Disease-modifying antirheumatic drugs. Using their clinical pharmacological effects as a guide to their selection. <b>1998</b> , 56, 337-44	19
503	Triple therapy with methotrexate, sulfasalazine, and hydroxychloroquine in patients with rheumatoid arthritis. <b>1998</b> , 24, 465-77	18
502	The Heberden Oration 1997. Treatment of rheumatoid arthritis: from symptomatic relief to potential cure. <b>1998</b> , 37, 1265-71	8
501	HLA-DRB1 typing in rheumatoid arthritis: predicting response to specific treatments. <b>1998</b> , 57, 209-13	76
500	Combination therapy in rheumatoid arthritis: updated systematic review. <b>1998</b> , 37, 612-9	65

499	New prospects for the treatment of rheumatoid arthritis. <b>1998</b> , 7, 1087-97	2
498	Rheumatoid arthritis. <b>1998</b> , 69, 6-13	4
497	Major histocompatibility complex-directed susceptibility to rheumatoid arthritis. <b>1998</b> , 68, 315-32	72
496	Use of cytotoxic agents and cyclosporine in the treatment of autoimmune disease. Part 1: rheumatologic and renal diseases. <b>1998</b> , 128, 1021-8	38
495	Rheumatoid arthritis. Designing and implementing a treatment plan. <b>1998</b> , 103, 103-6, 110, 116-8 passim	13
494	Rheumatology. <b>1998</b> , 316, 1810-2	3
493	Chondrex: new marker of joint disease. <b>1998</b> , 44, 509-516	138
492	New treatments for rheumatoid arthritis. Available and upcoming slow-acting antirheumatic drugs. <b>1999</b> , 106, 82-5, 88-90, 92	10
491	Combination therapy in rheumatoid arthritis. <b>1999</b> , 38, 789-790	
490	Anticytokine therapy--a new era in the treatment of rheumatoid arthritis?. <i>New England Journal of Medicine</i> , <b>1999</b> , 340, 310-2	59.2 96
489	Remodeling the therapeutic pyramid: evolving therapeutic strategies for rheumatoid arthritis. <b>1999</b> , 9, 1-16	
488	Medikamentöse Therapie der rheumatoiden Arthritis. <b>1999</b> , 28, 181-188	
487	Remodeling the therapeutic pyramid: evolving therapeutic strategies for rheumatoid arthritis. <b>1999</b> , 9, 1-16	
486	Efficacy and safety of a combination therapy of methotrexate, chloroquine and cyclophosphamide in patients with refractory rheumatoid arthritis: results of an observational study with matched-pair analysis. <b>1999</b> , 18, 145-51	11
485	The treatment of rheumatoid arthritis: a review of recent clinical trials. <b>1999</b> , 1, 135-8	2
484	Therapy of rheumatoid arthritis: new developments and trends. <b>1999</b> , 1, 149-56	6
483	Methotrexate and leflunomide: biochemical basis for combination therapy in the treatment of rheumatoid arthritis. <b>1999</b> , 29, 14-26	68
482	Recent advances in the treatment of rheumatoid arthritis. <b>1999</b> , 2, 38-50	8

481	Pharmacotherapeutic combination strategies with disease-modifying antirheumatic drugs in established rheumatoid arthritis. <b>1999</b> , 13, 689-700		5
480	Management of therapy-resistant rheumatoid arthritis. <b>1999</b> , 13, 737-52		3
479	Pharmacokinetics, safety, and efficacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritis. <b>1999</b> , 42, 1322-8		211
478	ACR 20: clinical or statistical significance?. <b>1999</b> , 42, 1572-6		37
477	A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. <i>New England Journal of Medicine</i> , <b>1999</b> , 340, 253-9	59.2	1781
476	Current status of gene therapy for rheumatoid arthritis. <b>1999</b> , 11, 103-14		
475	[Treatment of rheumatoid polyarthritis: evolution of concepts and strategies]. <b>1999</b> , 20, 171-8		13
474	Outstanding issues in use of disease-modifying agents in rheumatoid arthritis. <b>1999</b> , 353, 257-8		11
473	Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group. <b>1999</b> , 353, 1568-73		602
472	Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group. <b>1999</b> , 353, 259-66		588
471	Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. <b>1999</b> , 354, 1932-9		1960
470	Pain in the rheumatic diseases. Practical aspects of diagnosis and treatment. <b>1999</b> , 25, 15-30		9
469	Is there a role for antibiotics in the treatment of patients with rheumatoid arthritis?. <b>1999</b> , 57, 279-82		22
468	Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components. <b>1999</b> , 58, 220-5		168
467	Measuring the effects of medication use on health-related quality of life in patients with rheumatoid arthritis. A review. <b>1999</b> , 16, 433-48		22
466	Drug treatment for rheumatoid arthritis. <b>1999</b> , 22-30		9
465	Combination therapy with multiple disease-modifying antirheumatic drugs in rheumatoid arthritis: a preventive strategy. <b>1999</b> , 131, 768-74		84
464	Current and future trends in the use of immunosuppressive agents in patients with uveitis. <b>2000</b> , 11, 472-7		11

463	The course of radiologic damage during the first six years of rheumatoid arthritis. <b>2000</b> , 43, 1927-40	165
462	A cost-effectiveness analysis of treatment options for patients with methotrexate-resistant rheumatoid arthritis. <b>2000</b> , 43, 2316-27	85
461	Renal toxicity associated with disease-modifying antirheumatic drugs used for the treatment of rheumatoid arthritis. <b>2000</b> , 30, 196-208	50
460	Combination therapy with hydroxychloroquine, gold sodium thiomalate and methotrexate in early rheumatoid arthritis. An open 3-year study. <b>2000</b> , 19, 505-7	1
459	Medikamentöse Therapie der Rheumatoiden Arthritis. <b>2000</b> , 14, 193-206	3
458	Rheumatoid Arthritis. <b>2000</b> , 674-685	4
457	Biological agents: a novel approach to the therapy of rheumatoid arthritis. <b>2000</b> , 9, 1479-90	7
456	Clinical quality management in rheumatoid arthritis: putting theory into practice. Swiss Clinical Quality Management in Rheumatoid Arthritis. <b>2000</b> , 39, 542-9	69
455	A new era in rheumatoid arthritis treatment-time to introduce a modified treatment pyramid. <b>2000</b> , 93, 757-60	2
454	Current treatment paradigms in rheumatoid arthritis. <b>2000</b> , 39 Suppl 1, 30-5	44
453	Additive combination of actarit and methotrexate in the treatment of refractory rheumatoid arthritis. <b>2000</b> , 10, 103-9	3
452	Rheumatology Online: note from the Editor. <b>2000</b> , 39, 5-6	3
451	Resistant rheumatoid arthritis clinics- a necessary development?. <b>2000</b> , 39, 2-5	11
450	A 55-year-old woman with rheumatoid arthritis. <b>2000</b> , 283, 524-31	4
449	Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. <b>2000</b> , 130, 492-513	711
448	[Treatment of rheumatoid arthritis]. <b>2000</b> , 114, 777-83	
447	Are there differences in methotrexate kinetics between responding and nonresponding patients with rheumatoid arthritis?. <b>2000</b> , 13, 373-9	5
446	Tumour necrosis factor-alpha blockade: a new era for effective management of rheumatoid arthritis. <b>2000</b> , 1, 1041-52	30

445	Is it juvenile rheumatoid arthritis or fibromyalgia?. <b>2000</b> , 84, 967-82	7
444	Fármacos con actividad de fondo en patología inflamatoria articular (I). <b>2000</b> , 8, 1457-1463	
443	Actitudes terapéuticas. alimentación. actividad física. indicaciones de fisioterapia. indicaciones de tratamiento farmacológico. criterios de introducción y retirada de fármacos. indicaciones quirúrgicas. <b>2000</b> , 8, 1396-1401	
442	Criteria for TNF-targeted therapy in rheumatoid arthritis: estimates of the number of patients potentially eligible. <b>2001</b> , 61, 1711-20	11
441	Tumor necrosis factor-alpha blockade in the treatment of rheumatoid arthritis. <b>2001</b> , 27, 427-43	50
440	TNF-inhibition: The Need for a Tumor Necrosis Factor Thermostat. <b>2001</b> , 76, 573-575	8
439	Early rheumatoid arthritis: a medical emergency?. <b>2001</b> , 111, 498-500	24
438	Rheumatoid arthritis. Treatment of early disease. <b>2001</b> , 27, 405-14, x	29
437	Pharmacotherapy of rheumatoid arthritis: an overview. <b>2001</b> , 62, 92-112	11
436	Rheumatoid arthritis. <b>2001</b> , 358, 903-11	1051
435	Comorbidity in rheumatoid arthritis. <b>2001</b> , 27, 283-303	54
434	Combinations of conventional disease-modifying antirheumatic drugs. <b>2001</b> , 27, 415-26, x	6
433	New therapeutic approaches to the management of rheumatoid arthritis. <b>2001</b> , 15, 379-93	15
432	Combination therapy with disease modifying anti-rheumatic drugs in rheumatoid arthritis. <b>2001</b> , 15, 543-61	9
431	The 10th international rheumatology symposium in Tokyo "2001 frontier of rheumatology". <b>2001</b> , 11, 261-73	2
430	Current management of rheumatoid arthritis. <b>2001</b> , 36, 21-6, 29-30, 35	1
429	Combination therapy in rheumatoid arthritis. <b>2001</b> , 13, 177-83	24
428	Old and new drugs used in rheumatoid arthritis: a historical perspective. Part 2: the newer drugs and drug strategies. <b>2001</b> , 8, 163-79	20

427	Approaches to rheumatoid arthritis in 2000. <b>2001</b> , 13, 193-201	15
426	Prospects for autoimmune disease: Research advances in rheumatoid arthritis. <b>2001</b> , 285, 648-50	17
425	TNF alpha blockade in rheumatoid arthritis--time for caution or enthusiasm?. <b>2001</b> , 46, 67-70	1
424	Combination therapy in rheumatoid arthritis. <b>2001</b> , 23, 165-83	4
423	[Epidemiological and public health aspects of inflammatory rheumatic systemic diseases]. <b>2001</b> , 42, 211-6, 219-22	19
422	The effectiveness and toxicity of cyclosporin A in rheumatoid arthritis: longitudinal analysis of a population-based registry. <b>2001</b> , 45, 240-5	20
421	How is it best to treat early rheumatoid arthritis patients?. <b>2001</b> , 15, 125-37	10
420	Progress in the treatment of rheumatoid arthritis. <b>2001</b> , 286, 2787-90	62
419	Rational use of new and existing disease-modifying agents in rheumatoid arthritis. <b>2001</b> , 134, 695-706	128
418	The national database of the German Collaborative Arthritis Centres: II. Treatment of patients with rheumatoid arthritis. <b>2001</b> , 60, 207-13	30
417	The HLA-DRB1*0401 allele and the development of methotrexate-induced accelerated rheumatoid nodulosis: a follow-up study of 79 Caucasian patients with rheumatoid arthritis. <b>2001</b> , 80, 271-8	31
416	Treatment with cyclosporin switching to hydroxychloroquine in patients with rheumatoid arthritis. <b>2001</b> , 60, 514-7	5
415	Western and Chinese antirheumatic drug-induced T cell apoptotic DNA damage uses different caspase cascades and is independent of Fas/Fas ligand interaction. <b>2001</b> , 166, 6914-24	48
414	Kombinationstherapie der rheumatoiden Arthritis: Update 2001. <b>2001</b> , 26, 146-158	3
413	The Rheumatoid Hand. <b>2002</b> ,	3
412	Infliximab treatment in combination with cyclosporin A in patients with severe refractory rheumatoid arthritis. <b>2002</b> , 61, 822-5	34
411	Effective treatment of early rheumatoid arthritis with a combination of methotrexate, prednisolone and cyclosporin. <b>2002</b> , 41, 110-1	4
410	Analysis of improvements, full responses, remission and toxicity in rheumatoid patients treated with step-up combination therapy (methotrexate, cyclosporin A, sulphasalazine) or monotherapy for three years. <b>2002</b> , 41, 892-8	36



409	Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial. <b>2002</b> , 137, 726-33	222
408	Advances in the medical management of rheumatoid arthritis. <b>2002</b> , 63, 294-7	4
407	The evolving therapy of rheumatic diseases, the future is now. <b>2002</b> , 2, 1-11	2
406	Tumor necrosis factor-alpha blockade: a novel therapy for rheumatic disease. <b>2002</b> , 103, 231-42	70
405	Safety and efficacy of disease-modifying anti-rheumatic agents: focus on the benefits and risks of etanercept. <b>2002</b> , 25, 173-97	67
404	Current and future management approaches for rheumatoid arthritis. <b>2002</b> , 4 Suppl 2, S16-21	12
403	Treating rheumatoid arthritis early: a window of opportunity?. <b>2002</b> , 46, 283-5	194
402	Guidelines for the management of rheumatoid arthritis: 2002 Update. <b>2002</b> , 46, 328-46	1135
401	Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomized, double-blind, placebo-controlled trial. <b>2002</b> , 46, 1164-70	221
400	Cost effectiveness of adding leflunomide to a 5-year strategy of conventional disease-modifying antirheumatic drugs in patients with rheumatoid arthritis. <b>2002</b> , 47, 655-61	23
399	Termination of disease-modifying antirheumatic drugs in rheumatoid arthritis and in psoriatic arthritis. A comparative study of 270 cases. <b>2003</b> , 62, 155-60	23
398	Assessment of pain in patients with rheumatic diseases. <b>2003</b> , 17, 427-49	25
397	Treatment of early rheumatoid arthritis. <b>2003</b> , 17, 791-809	9
396	Pharmacological treatment of established rheumatoid arthritis. <b>2003</b> , 17, 811-29	22
395	Diagnostic value of high-resolution B-mode and doppler sonography for imaging of hand and finger joints in rheumatoid arthritis. <b>2003</b> , 48, 325-33	107
394	Guidelines for monitoring of methotrexate therapy: "evidence-based medicine" outside of clinical trials. <b>2003</b> , 48, 2706-9	8
393	Efficacy and safety of tacrolimus in patients with rheumatoid arthritis: a double-blind trial. <b>2003</b> , 48, 3328-37	86
392	Past, present and future drug treatment for rheumatoid arthritis and systemic lupus erythematosus. <b>2003</b> , 81, 350-3	20

391	[Methotrexate therapy in rheumatologic diseases--an update]. <b>2003</b> , 153, 291-4	
390	Therapeutic strategies for rheumatoid arthritis. <b>2003</b> , 2, 473-88	584
389	Adalimumab - a new TNF-alpha antibody for treatment of inflammatory joint disease. <b>2003</b> , 3, 351-60	20
388	Low dose methotrexate in inflammatory bowel disease: current status and future directions. <b>2003</b> , 98, 530-7	51
387	Long term structural effects of combination therapy in patients with early rheumatoid arthritis: five year follow up of a prospective double blind controlled study. <b>2003</b> , 62, 764-6	33
386	Cyclosporin A monotherapy versus cyclosporin A and methotrexate combination therapy in patients with early rheumatoid arthritis: a double blind randomised placebo controlled trial. <b>2003</b> , 62, 291-6	61
385	New concepts in the treatment of rheumatoid arthritis. <b>2003</b> , 54, 197-216	58
384	Infrared spectroscopy: shedding light on synovitis in patients with rheumatoid arthritis. <b>2003</b> , 42, 76-82	27
383	[Evidence-based treatment of methotrexate-resistant rheumatoid arthritis. Combinations of conventional disease-modifying antirheumatic agents]. <b>2003</b> , 128, 147-9	0
382	Is there still a role for traditional disease-modifying antirheumatic drugs (DMARDs) in rheumatoid arthritis?. <b>2003</b> , 15, 185-92	15
381	Population pharmacokinetics of hydroxychloroquine in patients with rheumatoid arthritis. <b>2003</b> , 25, 671-81	76
380	Progress in the treatment of rheumatic disease. <b>2003</b> , 18, 13-6	11
379	Current approaches to the treatment of parenchymal lung diseases. <b>2003</b> , 247-335	2
378	. <b>2003</b> ,	19
377	New drugs for rheumatoid arthritis. <i>New England Journal of Medicine</i> , <b>2004</b> , 351, 2659-61; author reply 2659-61	59.2 8
376	Low-dose tacrolimus treatment in thymectomised and steroid-dependent myasthenia gravis. <b>2004</b> , 20, 1269-73	31
375	A need for greater reporting of socioeconomic status and race in clinical trials. <b>2004</b> , 63, 1700-1	10
374	How aggressive should initial therapy for rheumatoid arthritis be? Factors associated with response to 'non-aggressive' DMARD treatment and perspective from a 2-yr open label trial. <b>2004</b> , 43, 619-25	14

373	The impact of new biologicals in the treatment of rheumatoid arthritis. <b>2004</b> , 43 Suppl 3, iii17-iii23	36
372	Two is better than one? Combination therapy in rheumatoid arthritis. <b>2004</b> , 43, 1205-7	11
371	Tumour necrosis factor inhibitors: risks and benefits in patients with rheumatoid arthritis. <b>2004</b> , 34, 687-93	43
370	Interleukin-17: the missing link between T-cell accumulation and effector cell actions in rheumatoid arthritis?. <b>2004</b> , 82, 1-9	67
369	Therapeutic advances in rheumatoid arthritis. <b>2004</b> , 7, 62-70	2
368	The use of methotrexate in rheumatoid arthritis. <b>2004</b> , 34, 465-83	87
367	[Internist's therapy of rheumatoid arthritis]. <b>2004</b> , 45, 693-705; quiz 706	0
366	Genetic markers of treatment response in rheumatoid arthritis. <b>2004</b> , 50, 1019-22	18
365	Classifying structural joint damage in rheumatoid arthritis as progressive or nonprogressive using a composite definition of joint radiographic change: a preliminary proposal. <b>2004</b> , 50, 1083-96	18
364	Toward a better understanding of methotrexate. <b>2004</b> , 50, 1370-82	379
363	Therapeutic cocktails for rheumatoid arthritis: the mixmaster's guide. <b>2004</b> , 50, 2041-3	8
362	Sulfasalazine is a potent inhibitor of the reduced folate carrier: implications for combination therapies with methotrexate in rheumatoid arthritis. <b>2004</b> , 50, 2130-9	61
361	The effect of folic acid and folinic acid supplements on purine metabolism in methotrexate-treated rheumatoid arthritis. <b>2004</b> , 50, 3104-11	43
360	Association of rheumatoid arthritis treatment response and disease duration with declines in serum levels of IgM rheumatoid factor and anti-cyclic citrullinated peptide antibody. <b>2004</b> , 50, 3776-82	96
359	Considerations with the use of biological therapy in the treatment of rheumatoid arthritis. <b>2004</b> , 3, 391-403	53
358	Appropriate and effective management of rheumatoid arthritis. <b>2004</b> , 63, 627-33	65
357	Clinical trials in rheumatic diseases: designs and limitations. <b>2004</b> , 30, 701-24, v-vi	17
356	Tratamiento de la artritis reumatoide. <b>2004</b> , 204, 273-282	0

355	Therapeutic strategies for rheumatoid arthritis. <i>New England Journal of Medicine</i> , <b>2004</b> , 350, 2591-602	59.2	416
354	Biological agents for rheumatoid arthritis: targeting both physical function and structural damage. <b>2004</b> , 64, 1267-83		61
353	Therapeutic effects of the combination of methotrexate and bucillamine in early rheumatoid arthritis: a multicenter, double-blind, randomized controlled study. <b>2005</b> , 15, 323-328		41
352	Tumor necrosis factor inhibitor therapy for rheumatoid arthritis. <b>2005</b> , 1051, 709-15		8
351	Do we need new treatment that goes beyond tumor necrosis factor blockers for rheumatoid arthritis?. <b>2005</b> , 1051, 799-810		33
350	New therapies for rheumatoid arthritis. <b>2005</b> , 140, 195-204		65
349	Inflammatory arthritis in the era of the biologics. <b>2005</b> , 5, 19-44		3
348	Therapeutic strategies in early rheumatoid arthritis. <b>2005</b> , 19, 163-77		55
347	The role of biologics in early rheumatoid arthritis. <b>2005</b> , 19, 179-89		4
346	Superior efficacy of combination therapy for rheumatoid arthritis: fact or fiction?. <b>2005</b> , 52, 2975-83		63
345	Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. <b>2005</b> , 52, 3381-90		1009
344	Tumor necrosis factor antagonists and infections: the small print on the price tag. <b>2005</b> , 53, 631-5		6
343	Progress toward the cure of rheumatoid arthritis? The BeSt study. <b>2005</b> , 52, 3326-32		23
342	Bibliography. <b>2005</b> , 649-682		
341	Antimalarials. <b>2005</b> , 347-372		
340	A meta-analysis of the efficacy and toxicity of combining disease-modifying anti-rheumatic drugs in rheumatoid arthritis based on patient withdrawal. <b>2005</b> , 44, 1414-21		102
339	Low-dose methotrexate: a mainstay in the treatment of rheumatoid arthritis. <b>2005</b> , 57, 163-72		391
338	Combination treatment strategies in early rheumatoid arthritis. <b>2005</b> , 64, 1252-6		10

337	Great expectations of modern RA treatment. <b>2005</b> , 64, 1249-51	7
336	Treatment of Rheumatoid Arthritis in the Elderly. <b>2005</b> , 35, 151-154	
335	Tratamiento de la artritis reumatoide. <b>2005</b> , 9, 1822-1829	
334	Sulfasalazine. <b>2005</b> , 93-132	
333	Rheumatic disease in the elderly: rheumatoid arthritis. <b>2005</b> , 21, 513-25, vi	20
332	A qualitative assessment of rheumatoid hand surgery in various regions of the world. <b>2005</b> , 30, 649-57	18
331	Efficacy, tolerability and cost effectiveness of disease-modifying antirheumatic drugs and biologic agents in rheumatoid arthritis. <b>2005</b> , 65, 661-94	77
330	Sulfasalazine: a review of its use in the management of rheumatoid arthritis. <b>2005</b> , 65, 1825-49	121
329	Tratamientos combinados en la artritis reumatoide. <b>2005</b> , 6, 151-161	1
328	Management issues with elderly-onset rheumatoid arthritis: an update. <b>2005</b> , 22, 809-22	39
327	Unmet needs in rheumatoid arthritis. <b>2005</b> , 7 Suppl 3, S2-8	20
326	Interleukin-6: a new therapeutic target. <b>2006</b> , 8 Suppl 2, S5	77
325	Artritis reumatoide del adulto: tratamiento. <b>2006</b> , 39, 1-26	
324	[Antimalarials: an update in rheumatic diseases]. <b>2006</b> , 2, 190-201	8
323	Mode of action of hydroxychloroquine in RA-evidence of an inhibitory effect on toll-like receptor signaling. <b>2006</b> , 2, 458-9	99
322	Real-world effectiveness of select biologic and DMARD monotherapy and combination therapy in the treatment of rheumatoid arthritis: results from the RADIUS observational registry. <b>2006</b> , 22, 185-98	53
321	Aspectos actuales y perspectivas de futuro del tratamiento de la artritis reumatoide. <b>2006</b> , 9, 4436-4442	
320	[Not Available]. <b>2006</b> , 2 Suppl 2, S1-8	2

319	Early rheumatoid arthritis: pitfalls in diagnosis and review of recent clinical trials. <b>2006</b> , 66, 1319-37	11
318	Biomarkers: Strategies to predict outcome of rheumatoid arthritis. <b>2006</b> , 3, 11-16	
317	Rheumatoid Arthritis. <b>2006</b> ,	
316	The use of low dose methotrexate in rheumatoid arthritis - are we entering a new era of therapeutic drug monitoring and pharmacogenomics?. <b>2006</b> , 60, 678-87	41
315	Treatment of early rheumatoid arthritis in developing countries. Biologics or disease-modifying anti-rheumatic drugs?. <b>2006</b> , 60, 688-92	15
314	Early combination disease modifying antirheumatic drug treatment for rheumatoid arthritis. <b>2006</b> , 184, 122-5	13
313	Potential role of statins and PPARs in rheumatoid arthritis. <b>2006</b> , 1, 259-274	2
312	Polyarthrite rhumatoïde de l'adulte : traitement. <b>2006</b> , 1, 1-23	1
311	Use of Anti-Infective Drugs in Rheumatology. <b>2006</b> , 5, 55-61	
310	Etanercept in severe active rheumatoid arthritis: first Australian experience. <b>2006</b> , 36, 625-31	7
309	Infliximab (Remicade® ): from bench to clinical practice. A paradigm shift in rheumatology practice. <b>2006</b> , 9, 107-118	3
308	Classic disease modifying anti-rheumatic drugs (DMARDs) in combination with infliximab. The Finnish experience. <b>2006</b> , 26, 741-8	17
307	Lipoxygenase inhibition: the neglected frontier for regulating chronic inflammation and pain. <b>2006</b> , 14, 99-102	7
306	Treatment of rheumatoid arthritis in the 21st century: targeting B-lymphocytes. <b>2006</b> , 156, 61-7	2
305	A mass spectrometric investigation of the binding of gold antiarthritic agents and the metabolite [Au(CN)2] <sup>-</sup> to human serum albumin. <b>2006</b> , 11, 559-70	43
304	Combination therapy for rheumatoid arthritis in the era of biologicals. <b>2006</b> , 2, 30-41	13
303	Positive influence of Methotrexate-Hydroxychloroquine combination on the expression of GM-CSF receptor on neutrophils of synovial fluid in rheumatoid arthritis. <b>2006</b> , 21, 49-52	1
302	The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. <b>2006</b> , 54, 26-37	1385

301	Methotrexate pharmacogenetics: the first step toward individualized therapy in rheumatoid arthritis. <b>2006</b> , 54, 1366-77	105
300	Relationship between genetic variants in the adenosine pathway and outcome of methotrexate treatment in patients with recent-onset rheumatoid arthritis. <b>2006</b> , 54, 2830-9	107
299	British Society for Rheumatology and British Health Professionals in Rheumatology Guideline for the Management of Rheumatoid Arthritis (The first 2 years). <b>2006</b> ,	5
298	Early rheumatoid arthritis: combination therapy of doxycycline plus methotrexate versus methotrexate monotherapy. <b>2006</b> , 2, 296-7	2
297	Infliximab for rheumatoid arthritis. <b>2006</b> , 2, 193-207	5
296	Are rheumatologists' treatment decisions influenced by patients' age?. <b>2006</b> , 45, 1555-7	48
295	Cutaneous abnormalities in rheumatoid arthritis compared with non-inflammatory rheumatic conditions. <b>2006</b> , 65, 1341-5	20
294	Abatacept improves both the physical and mental health of patients with rheumatoid arthritis who have inadequate response to methotrexate treatment. <b>2007</b> , 66, 189-94	50
293	Arthritis and its Treatment. <b>2006</b> , 105-132	5
292	Combination therapy with sulfasalazine and methotrexate is more effective than either drug alone in patients with rheumatoid arthritis with a suboptimal response to sulfasalazine: results from the double-blind placebo-controlled MASCOT study. <b>2007</b> , 66, 235-41	72
291	Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended study. <b>2006</b> , 65, 753-9	145
290	Leflunomide in the treatment of rheumatoid arthritis. <b>2006</b> , 2, 17-31	7
289	Should aggressive therapy for rheumatoid arthritis require early use of weekly low-dose methotrexate, as the first disease-modifying anti-rheumatic drug in most patients?. <b>2006</b> , 45, 497-9	7
288	Curcumin synergistically potentiates the growth-inhibitory and pro-apoptotic effects of celecoxib in osteoarthritis synovial adherent cells. <b>2006</b> , 45, 171-7	69
287	Treatment of elderly rheumatoid arthritis. <b>2007</b> , 2, 313-319	1
286	Methotrexate in rheumatoid arthritis. <b>2007</b> , 3, 27-33	6
285	Tacrolimus Treatment in Myasthenia Gravis. <b>2007</b> , 2, 53-56	2
284	Hydroxychloroquine and risk of diabetes in patients with rheumatoid arthritis. <b>2007</b> , 298, 187-93	190

283	Quantitative gait analysis as a method to assess mechanical hyperalgesia modulated by disease-modifying antirheumatoid drugs in the adjuvant-induced arthritic rat. <b>2007</b> , 9, R91	38
282	Combination therapy for rheumatoid arthritis: methotrexate and sulfasalazine together or with other DMARDs. <b>2007</b> , 3, 450-8; quiz, following 478	49
281	Rheumatic disease in the elderly: rheumatoid arthritis. <b>2007</b> , 33, 57-70	53
280	Rheumatoid arthritis. <b>2007</b> , 12, 525-37, vii	11
279	The BeSt way to treat early rheumatoid arthritis?. <b>2007</b> , 146, 459-60	5
278	Recent Advances in Inflammatory and Immunological Diseases: Focus on Arthritis Therapy. <b>2007</b> , 845-872	
277	Modernization Versus Limitation: Cross-Firing the Impact of the AHRQ Effective Health Care Program on Access to Biologic Therapies. <b>2007</b> , 13, 1-24	
276	The comparative safety and effectiveness of TNF-alpha antagonists [corrected]. <b>2007</b> , 13, S7-18	14
275	Resistance of rheumatoid arthritis patients to changing therapy: discordance between disease activity and patients' treatment choices. <b>2007</b> , 56, 2135-42	98
274	Treatment considerations in early rheumatoid arthritis. <b>1997</b> , 241, 445-9	
273	Clinical practice format for choosing a second-line disease modifying anti-rheumatic drug in early rheumatoid arthritis after failure of 6 months' first-line DMARD therapy. <b>2007</b> , 74, 73-8	15
272	Response-driven combination therapy with conventional disease-modifying antirheumatic drugs can achieve high response rates in early rheumatoid arthritis with minimal glucocorticoid and nonsteroidal anti-inflammatory drug use. <b>2007</b> , 37, 99-111	58
271	Cost effectiveness analysis of disease modifying antirheumatic drugs in rheumatoid arthritis. <b>2007</b> , 27, 1063-9	8
270	Arbre d'cisionnel permettant le choix en pratique clinique d'un traitement de fond de seconde intention au cours de la polyarthrite rhumatoïde récente, après échec d'un traitement de fond de première intention d'une durée de six mois. <b>2007</b> , 74, 79-84	
269	Clinical pharmacology of gold. <b>2008</b> , 16, 112-25	114
268	The burden of rheumatoid arthritis and access to treatment: a medical overview. <b>2008</b> , 8 Suppl 2, S39-47	16
267	Triple therapy in early active rheumatoid arthritis: a randomized, single-blind, controlled trial comparing step-up and parallel treatment strategies. <b>2008</b> , 58, 1310-7	75
266	American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. <b>2008</b> , 59, 762-84	1118



265	The immunopharmaceutical effects and mechanisms of herb medicine. <b>2008</b> , 5, 23-31	66
264	Toward a Non-Empirical Treatment for Rheumatoid Arthritis Based on Its Molecular Pathogenesis. <b>2008</b> , 4, 19-31	
263	Rheumatoid Arthritis. <b>2008</b> , 201-246	1
262	Poor Adherence to Medication in Adults with Rheumatoid Arthritis. <b>2008</b> , 16, 13-29	37
261	[Toward a non-empirical treatment for rheumatoid arthritis based on its molecular pathology]. <b>2008</b> , 4, 19-31	1
260	Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. <b>2008</b> , 372, 375-82	625
259	Stopping the rot: the stories behind methotrexate, sulphasalazine and hydroxychloroquine. <b>2008</b> , 11, 61-65	2
258	The rheumatic causes of elbow instability. <b>2008</b> , 24, 79-90	4
257	N-of-1 trials of expensive biological therapies: a third way?. <b>2008</b> , 168, 1030-3	18
256	The evolution of biomarkers in rheumatoid arthritis: from clinical research to clinical care. <b>2008</b> , 8, 1773-85	6
255	Discordant perspectives of rheumatologists and patients on COBRA combination therapy in rheumatoid arthritis. <b>2008</b> , 47, 1571-6	41
254	Tight control and intensified COBRA combination treatment in early rheumatoid arthritis: 90% remission in a pilot trial. <b>2008</b> , 67, 1574-7	52
253	Avonex Combination Trial in relapsing--remitting MS: rationale, design and baseline data. <b>2008</b> , 14, 370-82	21
252	Everolimus in patients with rheumatoid arthritis receiving concomitant methotrexate: a 3-month, double-blind, randomised, placebo-controlled, parallel-group, proof-of-concept study. <b>2008</b> , 67, 1090-5	67
251	Efficacy, safety, and tolerability of abatacept in the management of rheumatoid arthritis. <b>2009</b> , 1, 17-35	3
250	Recent Advance in Rheumatoid Arthritis. <b>2009</b> , 52, 657	2
249	Efficacy and toxicity of methotrexate (MTX) monotherapy versus MTX combination therapy with non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: a systematic review and meta-analysis. <b>2009</b> , 68, 1105-12	100
248	Evidenzbasierte Empfehlungen einer nationalen Expertenrunde zum Einsatz von Methotrexat bei entzündlich-rheumatischen Erkrankungen. <b>2009</b> , 34, 59-66	3

247	Methotrexate therapy in rheumatoid arthritis after failure to sulphasalazine: to switch or to add?. <b>2009</b> , 48, 1247-53	5
246	Drug-free remission, functioning and radiographic damage after 4 years of response-driven treatment in patients with recent-onset rheumatoid arthritis. <b>2009</b> , 68, 914-21	141
245	Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. <b>2009</b> , 68, 1086-93	320
244	Methotrexate in combination with sulfasalazine is more effective in rheumatoid arthritis patients who failed sulfasalazine than in patients naive to both drugs. <b>2009</b> , 48, 828-33	9
243	Facilitating the use of COBRA combination therapy in early rheumatoid arthritis: a pilot implementation study. <b>2009</b> , 36, 1380-6	3
242	Use of risk stratification to target therapies in patients with recent onset arthritis; design of a prospective randomized multicenter controlled trial. <b>2009</b> , 10, 71	30
241	Cytokines as targets for anti-inflammatory agents. <b>2009</b> , 1182, 88-96	8
240	[Methotrexate in rheumatology]. <b>2009</b> , 68, 747-56; quiz 757	7
239	Antibody responses to Porphyromonas gingivalis (P. gingivalis) in subjects with rheumatoid arthritis and periodontitis. <b>2009</b> , 9, 38-42	211
238	Treatment of rheumatoid arthritis: state of the art 2009. <b>2009</b> , 5, 531-41	170
237	Inflammation predicts accelerated brachial arterial wall changes in patients with recent-onset rheumatoid arthritis. <b>2009</b> , 11, R51	49
236	Randomized controlled trial design in rheumatoid arthritis: the past decade. <b>2009</b> , 11, 205	29
235	Guidelines for the use of conventional and newer disease-modifying antirheumatic drugs in elderly patients with rheumatoid arthritis. <b>2009</b> , 26, 273-93	19
234	Rheumatoid arthritis. <b>2009</b> , 373, 659-72	696
233	Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial. <b>2009</b> , 374, 459-66	223
232	Long-term outcomes of rheumatoid arthritis. <b>2009</b> , 21, 284-90	29
231	Update on the use of conventional disease-modifying antirheumatic drugs in the management of rheumatoid arthritis. <b>2010</b> , 22, 316-20	20
230	State-of-the-art: rheumatoid arthritis. <b>2010</b> , 69, 1898-906	215

229	Molecular imaging of rheumatoid arthritis by radiolabelled monoclonal antibodies: new imaging strategies to guide molecular therapies. <b>2010</b> , 37, 386-98	40
228	Pharmacotherapy: concepts of pathogenesis and emerging treatments. Challenges in clinical trial design in inflammatory arthritis. <b>2010</b> , 24, 457-61	1
227	Prediction of response to disease modifying antirheumatic drugs in rheumatoid arthritis. <b>2010</b> , 77, 558-63	20
226	Prédiction de la réponse aux traitements de fond antirhumatismaux (DMARD) dans la polyarthrite rhumatoïde. <b>2010</b> , 77, 590-595	
225	Suppression of antibody-mediated arthritis in mice by Fab fragments of the mediating antibodies. <b>2010</b> , 161, 1351-60	4
224	Medical Treatment of Rheumatoid Arthritis: A Review. <b>2010</b> , 28, 30-39	
223	First-line DMARD choice in early rheumatoid arthritis--do prognostic factors play a role?. <b>2010</b> , 49, 1267-71	15
222	Rheumatoid arthritis therapy: advances from bench to bedside. <b>2010</b> , 43, 478-92	24
221	Therapieschema der rheumatoiden Arthritis. Die Dreifachkombination Methotrexat plus Sulfasalazin plus Hydroxychloroquin ist mehr als nur eine Alternative zu Leflunomid. <b>2010</b> , 35, 129-131	0
220	Rheumatoid arthritis: a new challenge in coming era. <b>2010</b> , 10, 98-107	6
219	Methotrexate monotherapy versus methotrexate combination therapy with non-biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis. <b>2010</b> , CD008495	32
218	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. <b>2010</b> , 69, 964-75	1210
217	Current evidence for the management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. <b>2010</b> , 69, 1004-9	121
216	The effects of an orally administered probiotic on sulfasalazine metabolism in individuals with rheumatoid arthritis: a preliminary study. <b>2010</b> , 13, 48-54	23
215	Recent advances in rheumatoid arthritis. <b>2010</b> , 86, 243-50	10
214	Certolizumab pegol: a new biologic targeting rheumatoid arthritis. <b>2010</b> , 6, 855-66	15
213	Rheumatoid Arthritis. <b>2010</b> , 114-141	2
212	Unresolved issues in biologic therapy for rheumatoid arthritis. <b>2011</b> , 7, 205-15	27

211	Rheumatoid arthritis of the elbow. <b>2011</b> , 27, 139-50, v	11
210	Biologikatherapie in der Rheumatologie. <b>2011</b> , 2, e164-e166	
209	Biologic Foundations for Skeletal Tissue Engineering. <b>2011</b> , 3, 1-220	8
208	Safety of non-steroidal anti-inflammatory drugs, including aspirin and paracetamol (acetaminophen) in people receiving methotrexate for inflammatory arthritis (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, other spondyloarthritis). <b>2011</b> , CD008872	35
207	Shared experiences and best practices in the management of rheumatoid arthritis and Crohn's disease. <b>2011</b> , 124, e1-18	5
206	The microbiome and rheumatoid arthritis. <b>2011</b> , 7, 569-78	303
205	Hydroxychloroquine in systemic lupus erythematosus and rheumatoid arthritis and its safety in pregnancy. <b>2011</b> , 10, 705-14	61
204	The effects of disease modifying anti-rheumatic drugs on osteoclastogenesis and bone destruction in rheumatoid arthritis. <b>2011</b> , 34, 493-500	3
203	Ocular Complications of Drugs Used in Rheumatic Disease. <b>2011</b> , 7, 61-68	
202	The use of conventional disease-modifying anti-rheumatic drugs in established RA. <b>2011</b> , 25, 523-33	12
201	[Combination therapy using methotrexate with DMARDs or biologics--current status]. <b>2011</b> , 70, 114-22	4
200	Treating early rheumatoid arthritis intensively: current UK practice does not reflect guidelines. <b>2011</b> , 30, 103-6	8
199	Designing micro- and nano-particles for treating rheumatoid arthritis. <b>2011</b> , 34, 1887-97	58
198	Immune Modulation as Adjunctive Therapy for Pneumocystis pneumonia. <b>2011</b> , 2011, 918038	9
197	Treatment strategies in patients with rheumatoid arthritis for whom methotrexate monotherapy has failed: data from the NOR-DMARD register. <b>2011</b> , 70, 2103-10	16
196	Methotrexate: optimizing the efficacy in rheumatoid arthritis. <b>2011</b> , 3, 151-8	27
195	Use of hydroxychloroquine in Japan. <b>2012</b> , 39, 1296	7
194	Review of Rheumatology. <b>2012</b> ,	

193	Current and future role of methotrexate in the therapeutic armamentarium for rheumatoid arthritis. <i>International Journal of Clinical Rheumatology</i> , <b>2012</b> , 7, 179-189	1.5	9
192	In early rheumatoid arthritis, patients with a good initial response to methotrexate have excellent 2-year clinical outcomes, but radiological progression is not fully prevented: data from the methotrexate responders population in the SWEFOT trial. <b>2012</b> , 71, 186-91		67
191	Emerging therapies for pulmonary arterial hypertension: a review of recently completed and ongoing clinical trials. <b>2012</b> , 2, 491-501		
190	Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial. <b>2012</b> , 379, 1712-20		149
189	Initial management of rheumatoid arthritis. <b>2012</b> , 38, 311-25		15
188	Pie y artritis reumatoide. <i>EMC - Podologã</i> , <b>2012</b> , 14, 1-11	0	4
187	Correlates and predictors of disability in vulnerable US Hispanics with rheumatoid arthritis. <b>2012</b> , 64, 1274-81		32
186	A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial. <b>2012</b> , 64, 2824-35		271
185	Evolution of treatment for rheumatoid arthritis. <b>2012</b> , 51 Suppl 6, vi28-36		96
184	Rheumatoid Arthritis. <b>2012</b> , 1681-1689		2
183	Summary of AHRQ's comparative effectiveness review of drug therapy for rheumatoid arthritis (RA) in adults--an update. <b>2012</b> , 18, S1-18		23
182	Consenso 2012 da Sociedade Brasileira de Reumatologia para o tratamento da artrite reumatoide. <b>2012</b> , 52, 152-174		54
181	Incorporating the treat-to-target concept in rheumatoid arthritis. <b>2012</b> , 18, 1-18		6
180	Eficãcia terapõutica e seguranã de metotrexato + leflunomida em pacientes colombianos com artrite reumatoide ativa refratãria ao tratamento convencional. <b>2012</b> , 52, 837-845		10
179	Effects of long-term corticosteroid usage on functional disability in patients with early rheumatoid arthritis, regardless of controlled disease activity. <b>2012</b> , 32, 749-57		7
178	Efficacy of leflunomide addition in relation to prognostic factors for patients with active early rheumatoid arthritis failing to methotrexate in daily practice. <b>2012</b> , 31, 163-7		6
177	Old drugs, old problems: where do we stand in prediction of rheumatoid arthritis responsiveness to methotrexate and other synthetic DMARDs?. <b>2013</b> , 11, 17		50
176	Rheumatoid Arthritis. <b>2013</b> , 771-784		

175	Cost per responder of TNF- $\alpha$ therapies in Germany. <b>2013</b> , 32, 1805-9	3
174	Dendritic cells and the promise of antigen-specific therapy in rheumatoid arthritis. <b>2013</b> , 15, 204	34
173	Guidelines for the drug treatment of rheumatoid arthritis. <b>2013</b> , 53, 158-183	1
172	Diretrizes para o tratamento da artrite reumatoide. <b>2013</b> , 53, 158-183	16
171	Artritis reumatoide (II). <b>2013</b> , 11, 1850-1855	
170	Creative trial design in RA: optimizing patient outcomes. <b>2013</b> , 9, 183-94	12
169	Biological therapies for rheumatoid arthritis: progress to date. <b>2013</b> , 27, 329-45	21
168	Validation of the methotrexate-first strategy in patients with early, poor-prognosis rheumatoid arthritis: results from a two-year randomized, double-blind trial. <b>2013</b> , 65, 1985-94	53
167	Therapies for active rheumatoid arthritis after methotrexate failure. <i>New England Journal of Medicine</i> , <b>2013</b> , 369, 307-18	59.2 251
166	Rheumatoid arthritis: should we shift the focus from "Treat to Target" to "Treat to Work?". <b>2013</b> , 32, 285-7	12
165	Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in early rheumatoid arthritis: 2-year quality-of-life results of the randomised, controlled, SWEFOT trial. <b>2013</b> , 72, 1927-33	21
164	Trajectory of intensive treat-to-target disease modifying drug regimen in an observational study of an early rheumatoid arthritis cohort. <b>2013</b> , 3,	8
163	Polyarthrite rhumatoïde. <b>2013</b> , 97-136	
162	The 'therapeutic window' and treating to target in rheumatoid arthritis. <b>2013</b> , 13, 387-90	1
161	To what extent is NICE guidance on the management of rheumatoid arthritis in adults being implemented in clinical practice? A regional survey. <b>2013</b> , 13, 42-6	6
160	Current immunotherapy in rheumatoid arthritis. <b>2013</b> , 5, 955-74	79
159	Rheumatoid arthritis. Triple therapy or etanercept after methotrexate failure in RA?. <b>2013</b> , 9, 510-2	3
158	Pharmacokinetic consideration of synthetic DMARDs in rheumatoid arthritis. <b>2013</b> , 9, 969-81	

157	References. <b>2013</b> , 799-844	
156	Probiotics for Human and Poultry Use in the Control of Gastrointestinal Disease: A Review of Real-World Experiences. <b>2013</b> , 02,	3
155	Small Molecule DMARD Therapy and Its Position in RA Treatment. <b>2013</b> ,	1
154	Increasing obesity and comorbidity in patients undergoing primary total hip arthroplasty in the U.S.: a 13-year study of time trends. <b>2014</b> , 15, 441	35
153	Time trends in the characteristics of patients undergoing primary total knee arthroplasty. <b>2014</b> , 66, 897-906	53
152	Hand and foot surgery rates in rheumatoid arthritis have declined from 1986 to 2011, but large-joint replacement rates remain unchanged: results from two UK inception cohorts. <b>2014</b> , 66, 1081-9	83
151	Feasibility of tailored treatment based on risk stratification in patients with early rheumatoid arthritis. <b>2014</b> , 16, 430	5
150	Randomised controlled trial of tumour necrosis factor inhibitors against combination intensive therapy with conventional disease-modifying antirheumatic drugs in established rheumatoid arthritis: the TACIT trial and associated systematic reviews. <b>2014</b> , 18, i-xxiv, 1-164	17
149	Regular examinations for toxic maculopathy in long-term chloroquine or hydroxychloroquine users. <b>2014</b> , 132, 1199-208	38
148	Assessment of the treat-to-target strategy in patients with refractory rheumatoid arthritis. A prospective study on efficacy and safety in a Saudi population. <b>2014</b> , 73, 746-53	3
147	Methotrexate and lung disease in rheumatoid arthritis: a meta-analysis of randomized controlled trials. <b>2014</b> , 66, 803-12	121
146	Treatment of Autoimmune Disease: Established Therapies. <b>2014</b> , 1209-1220	
145	Sine Syndromes in Rheumatology. <b>2014</b> ,	
144	Therapeutic options after treatment failure in rheumatoid arthritis or spondyloarthritis. <b>2014</b> , 31, 780-802	1
143	Triple therapy in rheumatoid arthritis. <b>2014</b> , 10, 275-7	4
142	Triple therapy in rheumatoid arthritis. <b>2014</b> , 10, 275-277	
141	Randomised comparison of initial triple DMARD therapy with methotrexate monotherapy in combination with low-dose glucocorticoid bridging therapy; 1-year data of the tREACH trial. <b>2014</b> , 73, 1331-9	84
140	Efficacy of conventional synthetic disease-modifying antirheumatic drugs, glucocorticoids and tofacitinib: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. <b>2014</b> , 73, 510-5	106

139	Methotrexate for the treatment of rheumatoid arthritis in the biologic era: still an "anchor" drug?. <b>2014</b> , 13, 1102-8	55
138	Selection bias in rheumatic disease research. <b>2014</b> , 10, 403-12	69
137	Infliximab, methotrexate and their combination for the treatment of rheumatoid arthritis: a systematic review and meta-analysis. <b>2015</b> , 55, 146-158	
136	Making smart investment decisions in clinical research. <b>2015</b> , 16, 590	2
135	Safety and retention of combination triple disease-modifying anti-rheumatic drugs in new-onset rheumatoid arthritis. <b>2015</b> , 45, 1266-73	11
134	Risk of liver injury among methotrexate users: A meta-analysis of randomised controlled trials. <b>2015</b> , 45, 156-62	51
133	A Novel Small-Molecule Inhibitor Targeting the IL-6 Receptor $\beta$ Subunit, Glycoprotein 130. <b>2015</b> , 195, 237-45	51
132	Methotrexate revisited: considerations for subcutaneous administration in RA. <b>2015</b> , 34, 201-5	7
131	Infliximab, methotrexate and their combination for the treatment of rheumatoid arthritis: a systematic review and meta-analysis. <b>2015</b> , 55, 146-58	6
130	Inhibition of radiographic joint damage in rheumatoid arthritis patients in DAS28 remission using single- or combined with methotrexate non biological disease-modifying antirheumatic drug therapy in routine clinical practice. <b>2015</b> , 25, 50-5	3
129	Advances in the management of rheumatoid arthritis. <b>2015</b> , 60, 108-14	3
128	MIF and TNF $\beta$ erum levels in rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs: a cross-sectional study. <b>2015</b> , 37, 207-13	5
127	2014 Update of the Consensus Statement of the Spanish Society of Rheumatology on the Use of Biological Therapies in Rheumatoid Arthritis. <b>2015</b> , 11, 279-294	3
126	The optimal combination therapy for the treatment of early rheumatoid arthritis. <b>2015</b> , 16, 1615-25	9
125	2014 update of the Consensus Statement of the Spanish Society of Rheumatology on the use of biological therapies in rheumatoid arthritis. <b>2015</b> , 11, 279-94	60
124	Treatment of rheumatoid arthritis with methotrexate alone and in combination with other conventional DMARDs using the T2T strategy. A cohort study. <b>2015</b> , 34, 215-20	17
123	Prevalence of MTX Intolerance in Rheumatoid Arthritis- A 3 Year Prospective Hospital Based Study. <b>2016</b> , 6,	
122	Anti-malarials: Are There Benefits Beyond Mild Disease?. <b>2016</b> , 2, 1-12	5



121	MMP-3 as a predictor for structural remission in RA patients treated with MTX monotherapy. <b>2016</b> , 18, 55	19
120	Cost-effectiveness of adalimumab for rheumatoid arthritis in Germany. <b>2016</b> , 75, 1006-1015	8
119	Treatment of rheumatoid arthritis during pregnancy: present and future. <b>2016</b> , 12, 937-44	26
118	Active Rheumatoid Arthritis in Central Africa: A Comparative Study Between Sudan and Sweden. <b>2016</b> , 43, 1777-1786	10
117	Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis: A network meta-analysis. <b>2016</b> , CD010227	44
116	Improving patient-centred care for rheumatoid arthritis. <b>2016</b> , 188, 999-1000	
115	Neutropenia in the Elderly: A Rheumatology Perspective. <b>2016</b> , 33, 585-601	4
114	Artritis reumatoide del adulto: estrategias terapéuticas. <b>2016</b> , 49, 1-24	
113	Balancing benefits and risks of glucocorticoids in rheumatic diseases and other inflammatory joint disorders: new insights from emerging data. An expert consensus paper from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). <b>2016</b> , 28, 1-16	16
112	Strategies for the optimal use of biologic agents in rheumatoid arthritis. <b>2016</b> , 93-107	
111	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. <b>2017</b> , 76, 960-977	1649
110	Systematic review and network meta-analysis of the efficacy and safety of tumour necrosis factor inhibitor-methotrexate combination therapy versus triple therapy in rheumatoid arthritis. <b>2017</b> , 3, e000371	19
109	Triple Oral Therapy Versus Antitumor Necrosis Factor Plus Methotrexate (MTX) in Patients with Rheumatoid Arthritis and Inadequate Response to MTX: A Systematic Literature Review. <b>2017</b> , 44, 773-779	3
108	Triple Therapy Versus Biologic Therapy for Active Rheumatoid Arthritis: A Cost-Effectiveness Analysis. <b>2017</b> , 167, 8-16	29
107	Tratamiento de la artritis reumatoide. <b>2017</b> , 12, 1626-1638	2
106	A Multi-Biomarker Disease Activity Score and the Choice of Second-Line Therapy in Early Rheumatoid Arthritis After Methotrexate Failure. <b>2017</b> , 69, 953-963	22
105	Efficacy of triple association methotrexate, sulfasalazine and hydroxychloroquine in early treatment of rheumatoid arthritis with insufficient response to methotrexate: Meta-analysis of randomized controlled trials. <b>2017</b> , 84, 563-570	7
104	Efficacy and safety of tacrolimus for myasthenia gravis: a systematic review and meta-analysis. <b>2017</b> , 264, 2191-2200	16

103	Evidence-based recommendations for the diagnosis and management of rheumatoid arthritis for non-rheumatologists: Integrating systematic literature research and expert opinion of the Thai Rheumatism Association. <b>2017</b> , 20, 1142-1165	5
102	Treating rheumatoid arthritis to target: physician and patient adherence issues in contemporary rheumatoid arthritis therapy. <b>2017</b> , 23, 486-493	10
101	DNA methylation at diagnosis is associated with response to disease-modifying drugs in early rheumatoid arthritis. <b>2017</b> , 9, 419-428	25
100	Drugs for Autoimmune Inflammatory Diseases: From Small Molecule Compounds to Anti-TNF Biologics. <b>2017</b> , 8, 460	162
99	Traditional DMARDs: Methotrexate, Leflunomide, Sulfasalazine, Hydroxychloroquine, and Combination Therapies. <b>2017</b> , 958-982.e7	2
98	Therapies for Active Rheumatoid Arthritis after Methotrexate Failure. <b>2017</b> , 07,	
97	The Gut Microbiota and Inflammation in Rheumatoid Arthritis. <b>2017</b> ,	
96	Treatment of Rheumatoid Arthritis. <b>2017</b> , 1187-1212.e5	
95	Rheumatoid Arthritis. <b>2018</b> , 485-499	
94	Proceedings of the 2017 Santa Fe Bone Symposium: Insights and Emerging Concepts in the Management of Osteoporosis. <b>2018</b> , 21, 3-21	6
93	Efficacité de la triple association de méthotrexate, sulfasalazine et hydroxychloroquine dans le traitement précoce de la polyarthrite rhumatoïde lorsque la réponse au méthotrexate est insuffisante : méta-analyse d'essais comparatifs randomisés. <b>2018</b> , 85, 12-18	
92	Altered TNF- $\beta$ response by Aconibal $\alpha$ and methotrexate in a lipopolysaccharide-induced setting of inflammatory conditions: Potential on a synergistic combination. <b>2018</b> , 213, 191-197	7
91	Alzheimer's disease combination treatment. <b>2018</b> , 63, 165	10
90	An audit of the use of hydroxychloroquine in rheumatology clinics. <b>2018</b> , 2, rky013	3
89	Inadequate response to treat-to-target methotrexate therapy in patients with new-onset rheumatoid arthritis: development and validation of clinical predictors. <b>2018</b> , 77, 1261-1267	19
88	Comparison of Adults With Polyarticular Juvenile Idiopathic Arthritis to Adults With Rheumatoid Arthritis: A Cross-sectional Analysis of Clinical Features and Medication Use. <b>2019</b> , 25, 163-170	2
87	The use of methotrexate for treating childhood atopic dermatitis: a multicenter retrospective study. <b>2019</b> , 30, 240-244	8
86	JAK inhibition by methotrexate (and csDMARDs) may explain clinical efficacy as monotherapy and combination therapy. <b>2019</b> , 106, 1063-1068	27

85	Does Triple Conventional Synthetic Disease-Modifying Antirheumatic Drug Therapy Improve upon Methotrexate as the Initial Treatment of Choice for a Rheumatoid Arthritis Patient?. <b>2019</b> , 45, 315-324	1
84	Management of rheumatoid arthritis: 2019 updated consensus recommendations from the Hong Kong Society of Rheumatology. <b>2019</b> , 38, 3331-3350	11
83	Methotrexate in Patients With Rheumatoid Arthritis in Spain: Subanalysis of the AR Excellence Project. <b>2019</b> , 15, 338-342	
82	The importance of inhibition of a catabolic pathway of methotrexate metabolism in its efficacy for rheumatoid arthritis. <b>2019</b> , 122, 10-15	1
81	Methotrexate in patients with rheumatoid arthritis in Spain: Subanalysis of the AR Excellence project. <b>2019</b> , 15, 338-342	2
80	Efficacy and Safety of Combined Therapy With Synthetic Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis: Systematic Literature Review. <b>2020</b> , 16, 324-332	2
79	Plasma Leptin Does Not Reflect the Effect of High Body Mass Index on Disease Activity in Rheumatoid Arthritis. <b>2020</b> , 49, 32-45	5
78	Treatment of Autoimmune Disease: Established Therapies. <b>2020</b> , 1415-1435	
77	Efficacy and safety of combined therapy with synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis: Systematic literature review. <b>2020</b> , 16, 324-332	0
76	Drug repurposing to improve treatment of rheumatic autoimmune inflammatory diseases. <b>2020</b> , 16, 32-52	36
75	PIMD: An Integrative Approach for Drug Repositioning Using Multiple Characterization Fusion. <b>2020</b> , 18, 565-581	3
74	Leflunomide monotherapy versus combination therapy with conventional synthetic disease-modifying antirheumatic drugs for rheumatoid arthritis: a retrospective study. <b>2020</b> , 10, 12339	2
73	Candidate drug replacements for quinacrine in cutaneous lupus erythematosus. <b>2020</b> , 7,	1
72	Real-World Outcomes Associated With Methotrexate, Sulfasalazine, and Hydroxychloroquine Triple Therapy Versus Tumor Necrosis Factor Inhibitor/Methotrexate Combination Therapy in Patients With Rheumatoid Arthritis. <b>2021</b> , 73, 1114-1124	2
71	Circulating Small Noncoding RNA Biomarkers of Response to Triple Disease-modifying Antirheumatic Drug Therapy in White Women With Early Rheumatoid Arthritis. <b>2020</b> , 47, 1746-1751	1
70	Clinical Features, Diagnosis, and Treatment of Rheumatoid Arthritis. <b>2021</b> , 6, 41-60	1
69	Traditional and modern management strategies for rheumatoid arthritis. <b>2021</b> , 512, 142-155	6
68	Comprehensive Gut Microbiota and Drug Processing. <b>2021</b> ,	

67	The efficacy, safety and cost-effectiveness of hydroxychloroquine, sulfasalazine, methotrexate triple therapy in preventing relapse among patients with rheumatoid arthritis achieving clinical remission or low disease activity: the study protocol of a randomized controlled clinical Trial (ESCoRT study). <b>2021</b> , 21, 83	1
66	The positive effect of pregnancy in rheumatoid arthritis and the use of medications for the management of rheumatoid arthritis during pregnancy. <b>2021</b> , 29, 987-1000	3
65	The Therapeutic Landscape of Rheumatoid Arthritis: Current State and Future Directions. <b>2021</b> , 12, 680043	9
64	Antimalarial drugs-are they beneficial in rheumatic and viral diseases?-considerations in COVID-19 pandemic. <b>2021</b> , 1	3
63	Comparison between leflunomide and sulfasalazine based triple therapy in methotrexate refractory rheumatoid arthritis: an open-label, non-inferiority randomized controlled trial. <b>2021</b> , 1	1
62	Therapeutic effects of the combination of methotrexate and bucillamine in early rheumatoid arthritis: a multicenter, double-blind, randomized controlled study. <b>2005</b> , 15, 323-8	19
61	Methotrexate. <b>2015</b> , 443-450	3
60	Treatment of Rheumatoid Arthritis. <b>2009</b> , 1119-1143	4
59	Traditional DMARDs: Methotrexate, Leflunomide, Sulfasalazine, Hydroxychloroquine, and Combination Therapies. <b>2013</b> , 917-940.e6	2
58	Treatment of Rheumatoid Arthritis. <b>2013</b> , 1137-1160.e4	2
57	Screening for Fabry Disease in patients with unexplained left ventricular hypertrophy. <b>2020</b> , 15, e0239675	4
56	The plasma Tumor Necrosis Factor- $\alpha$ does not have any correlation with disease activity in rheumatoid arthritis patients treated with disease modifying anti-rheumatic drugs (DMARDs). <b>2009</b> , 3, 9-13	1
55	Sustained Remission After Combination Therapy with Rituximab and Etanercept in Two Patients with Rheumatoid Arthritis After TNF Failure: Case Report. <b>2009</b> , 3, 9-13	2
54	Rheumatoid arthritis. <b>2018</b> , 64, 98-106	2
53	TNF-inhibition: The Need for a Tumor Necrosis Factor Thermostat. <b>2001</b> , 76, 573-575	9
52	Methotrexate in rheumatoid arthritis. <b>2000</b> , 83-108	
51	Basistherapeutika und Immunsuppressiva. <b>2000</b> , 671-702	
50	Medikamentöse Therapie. <b>2001</b> , 425-509	

- 49 Immunglobuline bei Vaskulitiden und rheumatologischen Erkrankungen. **2001**, 203-214
- 48 Sulfasalazin rINN, USAN, Sulphasalazine BAN. **2001**, 674-679
- 47 History, Epidemiology and Clinical Evaluation of Rheumatoid Arthritis. **2002**, 1-8
- 46 Die Kerndokumentation als Instrument zur Erfassung, Steuerung und Qualitätssicherung neuer Therapien der rheumatoiden Arthritis. **2002**, 28-31
- 45 Combination therapy in rheumatoid arthritis. **2002**, 165-183
- 44 TNF-Inhibition in practical management of rheumatoid arthritis. **2004**, 99-120
- 43 Antirheumatika und Antiphlogistika. **2004**, 299-326
- 42 Antirheumatika und Antiphlogistika. **2004**, 388-411
- 41 Methotrexate. **2005**, 175-197
- 40 Combination therapy. **2005**, 293-318
- 39 Pharmacogenetics in Rheumatology. **2006**, 189-208
- 38 Pharmakotherapie. **2007**, 129-174
- 37 Rheumatoid Arthritis. **2009**, 1025-1038 1
- 36 Methotrexate, Leflunomide, Sulfasalazine, Hydroxychloroquine, and Combination Therapies. **2009**, 883-907 0
- 35 Other Traditional Disease-Modifying Antirheumatic Drugs: Monotherapy and Combination Therapy. **2009**, 325-336
- 34 Rheumatoid Arthritis. **2009**, 1-13
- 33 The efficacy of disease modifying anti-rheumatic drugs in rheumatoid arthritis in local patients of Karachi. *Pakistan Journal of Biological Sciences*, **2009**, 12, 339-45 0.8 2
- 32 Articular ultrasonography in rheumatoid arthritis. *International Journal of Clinical Rheumatology*, **2009**, 4, 583-595 1.5

- 31 Rheumatoid Arthritis. **2010**, 823-828
- 30 Parenteral gold, antimalarials, and sulfasalazine. **2011**, 505-507
- 29 Management of rheumatoid arthritis. **2011**, 955-963.e2
- 28 Rheumatology and Musculoskeletal Problems. **2012**, 648-689
- 27 Bone Scintigraphy in Arthritis. **2012**, 445-479
- 26 Atypical Course of Rheumatoid Arthritis. **2014**, 65-74
- 25 Pharmakotherapie. **2014**, 121-168
- 24 The Diagnosis and Treatment of Respiratory Infections in Autoimmune Disease, Excluding Tuberculosis. **1998**, 111-139
- 23 Nonimmunosuppressive disease-modifying antirheumatic drugs. **2015**, 434-442 1
- 22 Management of rheumatoid arthritis: synovitis. **2015**, 802-808 2
- 21 General Treatment Aspects. **2016**, 9-27
- 20 Rheumatoid Arthritis. **2017**, 1-15
- 19 Rheumatoid Arthritis. **2018**, 731-741
- 18 Rheumatoid arthritis: Treatment evolution over the years. **2020**, 5, 024-026 1
- 17 THE ROLE OF HYDROXYCHLOROQUINE IN THE TREATMENT OF HIV AND COVID-19: A REVIEW..  
**2020**, 9, 20-29
- 16 Systemic and Localized Inflammatory Diseases of Older Adults. **2022**, 243-257
- 15 Evaluating the Use of Hydroxychloroquine in Treating Patients With Rheumatoid Arthritis. *Cureus*,  
**2021**, 13, e19308 1.2 0
- 14 Antirheumatika und Antiphlogistika. 460-480

13	Historical and Current Perspectives on Management of Osteoarthritis and Rheumatoid Arthritis. <b>2008</b> , 5-36		1
12	A Review on Comparison of Effectiveness and Safety of Disease Modifying Anti-Rheumatoid Drugs Used in Patients with Rheumatoid Arthritis. <i>Journal of Drug Delivery and Therapeutics</i> , <b>2020</b> , 10, 207-212 <sup>1,3</sup>		
11	Rheumatoid arthritis. <i>Clinical Evidence</i> , <b>2007</b> , 2007,		1
10	Current imaging strategies in rheumatoid arthritis. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2012</b> , 2, 174-220	2.2	27
9	Methotrexate in rheumatoid arthritis: a quarter century of development. <i>Transactions of the American Clinical and Climatological Association</i> , <b>2013</b> , 124, 16-25	0.9	98
8	Pie y artritis reumatoide. <i>EMC - Podologā</i> , <b>2022</b> , 24, 1-13	0	
7	Selective Detection of Sulfasalazine Antibiotic and Controllable Photodegradation of Its into 5-Aminosalicylic acid by Visible-Light-Responsive Metalorganic Framework. <i>Dalton Transactions</i> ,	4.3	
6	Singapore Chapter of Rheumatologists Consensus Statement on the Eligibility for Government Subsidy of Biologic Disease Modifying Antirheumatic Agents for Treatment of Rheumatoid Arthritis (RA). <i>Annals of the Academy of Medicine, Singapore</i> , <b>2014</b> , 43, 400-411	2.8	3
5	Efficacy, safety, and cost-effectiveness of triple therapy in preventing relapse in rheumatoid arthritis: A randomized controlled trial (ESCoRT study). <b>2022</b> , 135, 2200-2209		0
4	Clinical and immunological effects of hydroxychloroquine in patients with active rheumatoid arthritis despite antirheumatic treatment.		0
3	Injectable Drug Delivery Systems for Osteoarthritis and Rheumatoid Arthritis.		1
2	Rheumatoid Arthritis. <b>2023</b> , 1-23		0
1	Pathogenesis of rheumatoid arthritis and its treatment with anti-inflammatory natural products.		0